LCM
PDLI

Laurion Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Laurion Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,712
Closed -$31K – 1474
2018
Q4 		$31K Buy
+10,712
New +$29.4K ﹤0.01% 1054

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Laurion Capital Management's PDLI Position: Q1 2019 in Review

Laurion Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2019, closing a stake of 10,712 shares — an estimated $31K sold.

Laurion Capital Management first reported a position in PDLI in Q4 2018 and held it in 1 quarter. The position peaked at $31K in Q4 2018. 157 funds tracked by Wall St. Rank hold PDLI as of Q1 2019.

  • Laurion Capital Management reported no remaining PDL BioPharma, Inc. position as of Q1 2019 after selling out during the quarter.
  • Laurion Capital Management sold 10,712 PDL BioPharma, Inc. shares in Q1 2019, an estimated $31K.
  • Laurion Capital Management first reported a position in PDL BioPharma, Inc. in Q4 2018 and held it in 1 quarter.
  • Laurion Capital Management's PDL BioPharma, Inc. position peaked at $31K in Q4 2018.
  • 157 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2019.

Based on Laurion Capital Management's 13F filing for Q1 2019, filed 8 May 2019.